ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of Rosetta's product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

    Contact:


    Media

    Alan Zachary

    T: +1-312-944-6784

    


    Investors

    Juliane Snowden

    T: +1-212-213-0006

    

media@mckinneychicago.com investors@rosettagenomics.com

CONTACT: Contact: Media, Alan Zachary, T: +1-312-944-6784,; Investors, Juliane Snowden, T: +1-212-213-0006, media@mckinneychicago.com investors@rosettagenomics.com

Ticker Symbol: (
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
2. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting
6. Sarasotas Roskamp Institute Announces Positive Safety Data in Human Clinical Study for Alzheimers Disease
7. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
8. Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue
9. Karmanos Physician-Scientists Examine Racial Disparities in Patients with Gynecologic Cancer
10. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
11. The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem Cells Work Better